Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma

Rheumatology

Volumn 38, Issue 11, 1999, Pages 1150-1152

  Protheroe, A ^a   Edwards, J C W ^b   Simmons, A ^a   Maclennan, K ^a   Selby, P ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti CD20; B lymphocyte; Lymphoma; Rheumatoid arthritis

Indexed keywords

MONOCLONAL ANTIBODY; PARAPROTEIN; RHEUMATOID FACTOR; RITUXIMAB;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; MALE; NONHODGKIN LYMPHOMA; POLYARTHRITIS; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS;

EID: 0032697669     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.11.1150     Document Type: Article

References (5)

1. Reff ME, Camer K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
2. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66.
3. Edwards JCW, Cambridge G. Rheumatoid arthritis: the predictable effect of small immune complexes in which antibody is also antigen. Br J Rheumatol 1998;37: 126-30.
4. Vial T, Descotes J. Immune-mediated side-effects of cyto-kines in humans. Toxicology 1995;105:31-57.
5. Edwards JCW. Is rheumatoid factor relevant? In: Bird HA, Snaith ML, eds. Challenges in rheumatoid arthritis. Chapter 1. Blackwell Scientific, 1999, pp. 1-24.